Written question asked by Damien Egan (Labour) on Monday, 26 January 2026, in the House of Commons. It was due for an answer on Wednesday, 28 January 2026. It was answered by Stephen Kinnock (Labour) on Monday, 2 February 2026 on behalf of the Department of Health and Social Care.
Skin Diseases: Steroid Drugs
- Question
-
To ask the Secretary of State for Health and Social Care, whether the upcoming integration of NHS England into the Department will affect the operation of Directed Enhanced Services or Structured Medication Reviews in relation to long-term topical steroid use.
- Answer
-
Work is progressing at pace to develop the design and operating model for the new integrated organisation, and to plan for the smooth transfer of people, functions, and responsibilities.
It is only right that with such significant reform, we commit to carefully assessing and understanding the potential impacts, as is due process. These ongoing assessments will inform our programme as appropriate.
At this stage, we do not anticipate any impacts on Structured Medication Reviews relating to long-term topical steroid use, nor on the operation of Directed Enhanced Services.
Secondary information
- Type
- Written question
- Reference
- 108326
- Session
- 2024-26
- Subjects
- Safety Steroid drugs Department of Health and Social Care NHS England Skin diseases
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-02-02 09:20:46 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/108326
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/108326
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/108326